# US 2024/0197729 A1 · ALK-5 Inhibitors and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197729 A1
- Document ID: US20240197729A1
- Status: Published application
- Kind: A1
- Application number: 18/552,492
- Filed: 2022-03-25
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Assignees: Sumitomo Pharma Oncology, Inc.
- Applicants: Sumitomo Pharma Oncology, Inc.
- Inventors: Bettina Franz; Adam Siddiqui-Jain; Steven L. Warner
- Web page: https://patentgrep.com/patent/US20240197729A1

## CPC

- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are compounds (e.g., compounds of Formulae (I), (II), (III) and (IV), compounds listed in Table 1) and pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and kits comprising the same. The compounds provided herein are activin receptor-like kinase (e.g., ALK-5) inhibitors and are useful for treating and/or preventing diseases (e.g., proliferative diseases, e.g., cancer) in a subject, for inhibiting tumor growth in a subject, and/or for inhibiting the activity of an activin receptor-like kinase (e.g., ALK-5) in vitro or in vivo.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a C1-C5 alkyl, C3-C5 carbocycle, or halogen;
R2 is —H, a halogen, a C1-C3 alkyl optionally substituted with one or more —F, or a cyclopropyl optionally substituted with one or more —F;
R3 is —H, a halogen, a C1-C3 alkyl optionally substituted with one or more —F, or a cyclopropyl optionally substituted with one or more —F; and
Ring G is
wherein
indicates the point of attachment of Ring G to the —N(H)—; or
Ring G is a C6-C10 aryl optionally substituted with:
(i) one or more halogens;
(ii) a sulfonamide;
(iii) a monocyclic, bicyclic or spirocyclic C3-C10 carbocycle which is optionally substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen, wherein said carbocycle is attached to Ring G by a single bond or a methylene or ethylene linker at a position on Ring G which is meta- or para- to the —N(H)— attached to Ring G; or
(iv) a monocyclic, bicyclic, bridged or spirocyclic C3-C10 heterocycle which may contain up to 3 heteroatoms independently selected from N and O and which is optionally and independently substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen, wherein said heterocycle is attached to Ring G by a single bond or a methylene or ethylene linker at a position on Ring G which is meta- or para- to the —N(H)— attached to Ring G.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is a C1-C5 alkyl or C3-C5 carbocycle.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is a halogen.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is methyl, cyclopropyl or chloro.

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein R2 is —H, a halogen, —CH3, —CF3 or cyclopropyl.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R2 is —H.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R3 is —H, a halogen, —CH3, —CF3 or cyclopropyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R3 is —H.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein Ring G is

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein Ring G is a C6-C10 aryl substituted with:
(i) one or more halogens;
(ii) a sulfonamide;
(iii) a monocyclic, bicyclic or spirocyclic C3-C10 carbocycle which is optionally substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen, wherein said carbocycle is attached to Ring G by a single bond or a methylene or ethylene linker at a position on Ring G which is meta- or para- to the —N(H)— attached to Ring G; or
(iv) a monocyclic, bicyclic, bridged or spirocyclic C3-C10 heterocycle which may contain up to 3 heteroatoms independently selected from N and O and which is optionally and independently substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen, wherein said heterocycle is attached to Ring G by a single bond or a methylene or ethylene linker at a position on Ring G which is meta- or para- to the —N(H)— attached to Ring G.

### Claim 11 (depends on 10)

The compound of claim 10, wherein Ring G is substituted with:
i) one or more halogens;
ii) a sulfonamide;
iii) a monocyclic, bicyclic or spirocyclic C3-C10 carbocycle which is optionally substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen, wherein said carbocycle is attached to Ring G by a single bond or a methylene or ethylene linker at a position on Ring G which is meta- or para- to the —N(H)— attached to Ring G;
iv) a monocyclic C3-C7 carbocycle which is optionally substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen; or
v) a cyclohexyl which is optionally substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen.

### Claim 12 (depends on 10, 11)

The compound of claim 10 or 11, wherein the carbocycle that is attached to Ring G is unsubstituted.

### Claim 13 (depends on 10)

The compound of claim 10, wherein Ring G is substituted with a monocyclic, bicyclic, bridged or spirocyclic C3-C10 heterocycle which may contain up to 3 heteroatoms independently selected from N and O and which is optionally and independently substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen, wherein said heterocycle is attached to Ring G by a single bond or a methylene or ethylene linker at a position on Ring G which is meta- or para- to the —N(H)— attached to Ring G.

### Claim 14 (depends on 13)

The compound of claim 13, wherein Ring G is substituted with a monocyclic C5-C6 heterocycle which may contain up to 3 heteroatoms independently selected from N and O and which is optionally and independently substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen.

### Claim 15 (depends on 14)

The compound of claim 14, wherein Ring G is substituted with a piperazinyl, morpholinyl, piperidinyl or oxanyl, which is optionally and independently substituted with one or more C1-C6 alkyl or C3-C6 carbocycle which are optionally substituted with hydroxy or one or more halogen.

### Claim 16 (depends on 13, 14, 15)

The compound of any one of claims 13-15, wherein the heterocycle that is attached to Ring G is unsubstituted or monosubstituted.

### Claim 17 (depends on 16)

The compound of claim 16, wherein the heterocycle that is attached to Ring G is unsubstituted.

### Claim 18 (depends on 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 10-17, wherein the carbocycle or heterocycle that is attached to Ring G is optionally and independently substituted with methyl, CF3CH2— or HOCH2CH2—.

### Claim 19 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 10-18, wherein the carbocycle or heterocycle attached to Ring G is attached to Ring G at a position on Ring G which is meta- to the —N(H)— attached to Ring G.

### Claim 20 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 10-18, wherein the carbocycle or heterocycle attached to Ring G is attached to Ring G at a position on Ring G which is para- to the —N(H)— attached to Ring G.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound of any one of claims 1-20, wherein the C6-C10 aryl of Ring G is phenyl.

### Claim 22 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, having the following structure:
or a pharmaceutically acceptable salt thereof, wherein:
Ring J is attached to the phenylene at a position which is meta- or para- to the —N(H)— attached to the phenylene;
A1 is —N(R4)—, —O— or >C(H)(R4);
R4 is —H, or a C1-C6 alkyl or C3-C6 carbocycle, each of which is optionally substituted with hydroxy or one or more halogen;
A2 is >N— or >C(H)—;
Z is >CH2; and X and Y are independently >CH2 or >C(CH3)2, or X and Y are both >CH— and are bonded together through a methylene or ethylene bridge; or
Y is >CH2 or >C(CH3)2, and X and Z are both >CH— and are bonded together through a methylene or ethylene bridge; and
n is 0, 1 or 2.

### Claim 24 (depends on 23)

The compound of claim 23, wherein A1 is >C(H)(R4).

### Claim 25 (depends on 23)

The compound of claim 23, wherein A1 is —N(R4)— or —O—.

### Claim 26 (depends on 23, 24, 25)

The compound of any one of claims 23-25, wherein R4 is —H, or a C1-C6 alkyl, which is optionally substituted with hydroxy or one or more halogen.

### Claim 27 (depends on 26)

The compound of claim 26, wherein R4 is —H, methyl, hydroxyethyl or trifluoroethyl.

### Claim 28 (depends on 23, 24, 25, 26, 27)

The compound of any one of claims 23-27, wherein A2 is >C(H)—.

### Claim 29 (depends on 23, 24, 25, 26, 27, 28)

The compound of any one of claims 23-28, wherein A2 is >N—.

### Claim 30 (depends on 23)

The compound of claim 23, wherein Ring J is:

### Claim 31 (depends on 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 23-30, wherein Ring J is attached to the phenylene at a position which is meta- to the —N(H)— attached to the phenylene.

### Claim 32 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 23-31, wherein n is 0 or 1.

### Claim 33 (depends on 32)

The compound of claim 32, wherein n is 0.

### Claim 34 (depends on 1, 2, 3, 4, 23, 24, 25, 26, 27, 28, 29, 31)

The compound of any one of claims 1-4, 23-29 and 31, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 34)

The compound of claim 34, wherein Ring J is:

### Claim 36

A compound, or a pharmaceutically acceptable salt thereof, having the structure:

### Claim 37 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 38 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 41 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 36)

The compound of claim 36, wherein the compound is of the following formula:
or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A pharmaceutical composition comprising a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A pharmaceutical combination comprising a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45, and one or more additional therapeutic agents.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of treating a proliferative disease in a subject, the method comprising administering to the subject a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45.

### Claim 48 (depends on 47)

The method of claim 47, wherein the proliferative disease is cancer.

### Claim 49 (depends on 48)

The method of claim 48, wherein the cancer is a hematological cancer.

### Claim 50 (depends on 48)

The method of claim 48, wherein the cancer comprises a solid tumor.

### Claim 51 (depends on 48)

The method of claim 48, wherein the cancer is lung cancer, brain cancer, thyroid cancer, anaplastic astrocytoma, liver cancer, pancreatic cancer, skin cancer, melanoma, metastatic melanoma, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, ovarian cancer, an HPV-associated cancer, multiple myeloma, myelodysplastic syndrome, a hematological cancer, or myelofibrosis.

### Claim 52 (depends on 48)

The method of claim 48, wherein the cancer is non-small cell lung cancer (NSCLC), neuroblastoma, glioblastoma, anaplastic thyroid cancer (ATC), colon carcinoma, hepatocellular carcinoma (HCC), pancreatic carcinoma, anaplastic large cell lymphoma (ALCL), myelodysplastic syndrome, anaplastic astrocytoma or pancreatic ductal adenocarcinoma.

### Claim 53 (depends on 48)

The method of claim 48, wherein the cancer is an adult granulosa cell tumor.

### Claim 54 (depends on 48)

The method of claim 48, wherein the cancer is an HPV-associated cancer selected from cervical cancer, oropharyngeal cancer, anal cancer, vulvar/vaginal cancer, or penile cancer.

### Claim 55 (depends on 47)

The method of claim 47, wherein the proliferative disease is a fibrotic condition.

### Claim 56 (depends on 55)

The method of claim 55, wherein the fibrotic condition is idiopathic pulmonary fibrosis, cardiac fibrosis, a condition associated with cardiac fibrosis, valvular disease, arrhythmia, atrial fibrillation, myocardial remodeling, cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, hypertrophic cardiomyopathy, restenosis, liver fibrosis, liver cirrhosis, nonalcoholic steatohepatitis, Peyronie's, Dupuytren's contracture, cystic fibrosis, beta thalassemia, actinic keratosis, hypertension, a general inflammatory disorder, dry eye, ulcer, corneal fibrosis, wet age-related macular degeneration, psoriasis, wound closure, chronic kidney disease, renal fibrosis, systemic sclerosis, or chronic Chagas' heart disease.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of inhibiting tumor growth in a subject, the method comprising administering to the subject a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of inhibiting ALK-5 activity in vivo or in vitro, the method comprising contacting ALK-5 with a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of treating an inflammatory disease, disorder, or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45.

### Claim 60 (depends on 59)

The method of claim 59, wherein the inflammatory disease, disorder, or condition is non-alcoholic fatty liver disease (NAFLD), alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis, autoimmune hepatitis, skin inflammation, or psoriasis.

### Claim 61 (depends on 59, 60)

The method of claim 59 or 60, wherein the inflammatory disease, disorder, or condition is an autoimmune disease, disorder, or condition.

### Claim 62 (depends on 61)

The method of claim 61, wherein the autoimmune disease, disorder, or condition is osteoarthritis, rheumatoid arthritis, pain, inflammatory bowel disease, a respiratory disorder, or a skin disorder.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of treating a fibrotic, inflammatory or proliferative disease or condition which is susceptible to inhibition of the TGFβ signaling pathway, the method comprising administering to a subject suffering from the fibrotic, inflammatory or proliferative disease or condition a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45, in an amount effective to inhibit TGFβ signaling.

### Claim 64 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63)

The method of any one of claims 47-57 and 59-63, wherein the subject is a human.

### Claim 65 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 64)

The method of any one of claims 47-57 and 59-64, wherein the proliferative disease, inflammatory disease, disorder or condition, tumor, cancer, or fibrotic, inflammatory or proliferative disease or condition expresses or has mutant forkhead box L2 (FOXL2) or FOXL2.

### Claim 66 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 47-57 and 59-65, further comprising administering one or more additional therapeutic agents to the subject selected from an anti-cancer agent and an immune checkpoint inhibitor.

### Claim 67 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 47-57 and 59-66, further comprising treating the subject with radiation therapy or surgery.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of inhibiting epithelial to mesenchymal transition (EMT) in a subject suffering from a disease or condition which is promoted by EMT, comprising administering at least one compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45 to the subject in an amount effective to sufficiently inhibit EMT to alter the course of the disease or condition.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for enhancing the activity of one or more therapeutic agents for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 45.

### Claim 70 (depends on 69)

The method of claim 69, further comprising administering to the subject one or more therapeutic agents selected from an anti-cancer agent or an immune checkpoint inhibitor.

### Claim 71 (depends on 66, 67, 70)

The method of claim 66, 67 or 70, wherein the immune checkpoint inhibitor is a PD-1 or PD-L1 inhibitor.
